Current trends in lead discovery: Are we looking for the appropriate properties?

Journal of Computer-Aided Molecular Design

Volumn 16, Issue 5-6, 2002, Pages 325-334

  Oprea, Tudor ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

'Rule of 5' test; Database filtering; Drug research; Drug likeness; Hydrophobicity; Leda likeness; Property distribution; Solubility

Indexed keywords

ALCOHOLS; BINDING ENERGY; BIOACTIVITY; DRUG DELIVERY; HYDROPHOBICITY;

'CURRENT; 'RULE OF 5' TEST; CANDIDATE DRUGS; DATABASE FILTERING; DRUG RESEARCH; DRUG-LIKENESS; LEDA-LIKENESS; PHASE I; PROPERTY; PROPERTY DISTRIBUTION;

SOLUBILITY;

BUTACLAMOL; CLOZAPINE; ENZYME INHIBITOR; METHYLPHENIDATE; OMEPRAZOLE; RECEPTOR BLOCKING AGENT;

BINDING AFFINITY; CLINICAL STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MARKETING; DRUG QUALITY; DRUG RESEARCH; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROPHOBICITY; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; MEDICAL TECHNOLOGY; MOLECULAR WEIGHT; PARTITION COEFFICIENT; PRIORITY JOURNAL; PROBABILITY; REVIEW; ARTICLE; CHEMISTRY; DRUG DESIGN;

CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; MOLECULAR WEIGHT;

EID: 0036589285     PISSN: 0920654X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020877402759     Document Type: Review

References (23)

1. The top 50 pharmaceutical companies have spent, on the average, 750 millions USD for each of the 21 truly novel drugs launched during the past decade [2].
2. Drews, J., Drug Discov. Today, 3 (1998) 491-494.
3. Horrobin, D.F., J. R. Soc. Med., 93 (2000) 341-345.
4. Olsson, T. and Oprea, T.I. Curr. Op Drug Discov. Dev., 4 (2001) 308-313.
5. Lebl, M., J. Comb. Chem., 1 (1999) 3-24.
6. Martin, Y.C., J. Comb. Chem. 3 (2001) 231-250.
7. Fox, S., Farr-Jones, S. and Yund, M.A., J. Biomol. Screening, 4 (1999) 183-186.
8. Oprea, T.I., Curr. Op. Chem. Biol., 6 (2002) 384-389.
9. Rishton, G.M., Drug Discov. Today, 2 (1997) 382-384.
10. DeStevens, G., Prog. Drug. Res., 30 (1986) 189-203.
11. Oprea, T.I., Davis, A.M., Teague, S.J. and Leeson, P.D., J. Chem. Inf. Comput. Sci., 41 (2001) 1308-1315.
12. Boyd, D.B., In: Liljefors, T., Jorgensen, F.S., Krogsgaard-Larsen, P. (eds.) Rational Molecular Design in Drug Research, Munksgaard, Copenhagen, (1998) 15-29.
13. Kennedy, T., Drug Discov. Today, 2 (1997) 436-444.
14. Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J., Adv. Drug. Deliv. Rev., 23 (1997) 3-25.
15. Teague, S.J., Davis, A.M., Leeson, P.D. and Oprea, T.I., Angew. Chem. Int, Ed., 38 (1999) 3743-3748. German version: Angew. Chem., 111 (1999) 3962-3967.
16. Hann, M.M., Leach, A.R. and Harper, G., J. Chem. Inf. Comput. Sci., 41 (2001) 856-864.
17. Meylan, W.M. and Howard, P.H., J. Pharm. Sci., 84 (1995) 83-92. KOWWIN v1.6 is available from US EPA, http://www.epa.gov/oppt/exposure/docs/episuited1.htm
18. Meylan, W.M., Howard, P.H. and Boethling, R.S., Environ. Toxicol. Chem., 15 (1996) 100-106. WSKOWIN 1.40 is available from US EPA, http://www.epa.gov/oppt/exposure/docs/episuited1.htm
19. Available from MDL Information Systems, http://www.mdli.com/dats/pharmdb.htmi. The MDDR database is developed in cooperation with Prous Science Publishers, http://www.prous.com/index.html. The search was conducted using the 2001.2 release.
20. The following publications were included in this survey: Journal of Medicinal Chemistry volumes 40 (1997) and 41 (1998) - forming over 90% of the structures analysed; Quantitative Structure Activity Relationships volumes 17 (1998), 18 (1999), and 19 (2000), as well as European Journal of Medicinal Chemistry volume 36 (2001).
21. Lipinski, C.A., J. Pharmacol Toxicol Meth., 44 (2000) 235-249.
22. Kuntz, I.D., Chen, K., Sharp, K.A. and Kollman, P.A., Proc. Natl. Acad. Sci. USA, 96 (1999) 9997-10002.
23. Oprea, T.I., Molecules, 7 (2002) 55-64.